Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
LOS ANGELES, CA, April 27, 2018 -- Hoverink Biotechnologies, Inc announced today it intends to offer, subject to market and other conditions, $2.5 million of Series A Convertible Notes, through a Regulation D 506(b) offering to qualified buyers. The Notes would be convertible into Hoverink common stock and would have a two-year term. the Notes and the common stock issuable upon conversion of the Notes have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and unless so registered, may not be offered or sold in the United States, except pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended, and any state securities laws.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Notes. Hoverink Biotechnologies, Inc., headquartered in Los Angeles, CA, is an independent preclinical biopharmaceutical company. The Company develops, manufactures, and commercializes pharmaceutical preparations and drug treatment for age-related diseases, cancer, mental illnesses, and gastrointestinal and oncological disorders. Hoverink Biotechnologies serves patients in the United States.
In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties, including but not limited to, uncertainties related to the offering of the notes. Actual results could differ materially. for more information on Hoverink Biotechnologies, Inc. please visit the company's web site at http://www.hoverinkbiotech.yolasite.com/ or call the Hoverink Biotechnologies Corporate Communications Department at 866-443-4666 EXT 113
Contact: Cyrus Sajna Vice-President Hoverink Biotechnologies Inc, 1801 CENTURY PARK EAST, 24TH FLOOR LOS ANGELES, CA 90067 [email protected] 866-443-4666
